Get the Stockscreener App
0.728
1.29%
-0.0239
After Hours:
.75
0.022
+3.02%
Matinas Biopharma Holdings Inc stock is traded at $0.728, with a volume of 110.20K.
It is down -1.29% in the last 24 hours and up +13.93% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.7041
Open:
$0.6623
24h Volume:
110.20K
Relative Volume:
0.86
Market Cap:
$4.66M
Revenue:
$1.10M
Net Income/Loss:
$-11.23M
P/E Ratio:
-0.3595
EPS:
-2.025
Net Cash Flow:
$-6.61M
1W Performance:
+24.78%
1M Performance:
+13.93%
6M Performance:
-4.79%
1Y Performance:
-14.41%
1-Day Range:
$0.65
$0.7931
1-Week Range:
$0.4838
$0.7931
52-Week Range:
$0.48
$3.09
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.728 | 4.51M | 1.10M | -11.23M | -6.61M | -2.025 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
MSN Money - MSN
MTNB Q4 2024 Earnings: Matinas Biopharma Reports Narrower-Than-Expected LossAnalyst Consensus Shift - Newser
MTNB Technical Analysis | Trend, Signals & Chart Patterns | MATINAS BIOPHARMA HOLDINGS I (NYSEARCA:MTNB) - ChartMill
Matinas Biopharma Holdings, Inc. Common Stock (NY: MTNB - The Chronicle-Journal
MTNB Stock Price, Quote & Chart | MATINAS BIOPHARMA HOLDINGS I (NYSEARCA:MTNB) - ChartMill
TradingKey - TradingKey
What Matinas (MTNB) is building for next year | Q4 2024: Earnings Beat EstimatesProfessional Trade Ideas - Newser
Matinas BioPharma (NYSE: MTNB) warns on going concern amid low cash and NYSE notice - Stock Titan
The edge Matinas (MTNB) has in a competitive landscape (-1.09%) 2026-05-08Real Trader Insights - Newser
What Matinas (MTNB) does that makes it resilient (Institutional Selling) 2026-05-08Social Momentum Signals - newser.com
Net current asset value per share of Matinas BioPharma Holdings, Inc. – FWB:6LJ0 - TradingView
Operating cash flow per share of Matinas BioPharma Holdings, Inc. – FWB:6LJ0 - TradingView
Matinas BioPharma Holdings, Inc. (MTNB) - Minichart
Sell Signal: Will Matinas BioPharma Holdings Inc benefit from government policy2026 Bull vs Bear & Expert Curated Trade Setups - baoquankhu1.vn
Aug Setups: Can Matinas BioPharma Holdings Inc generate free cash flow2026 Fed Impact & Verified Chart Pattern Signals - baoquankhu1.vn
Analyst Upgrade: Can Matinas BioPharma Holdings Inc ride the EV waveJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Aug Wrap: What are the risks of holding Matinas BioPharma Holdings Inc2026 Earnings Surprises & High Accuracy Trade Alerts - baoquankhu1.vn
SHPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Matinas BioPharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity and Ongoing Losses 1 - Minichart
SHPH PE Ratio & Valuation, Is SHPH Overvalued - Intellectia AI
Matinas BioPharma Faces NYSE Compliance Issues - Intellectia AI
Heritage Signs & Displays Completes JD Lewis Center Transformative Branding Project in Raleigh, NC - Weekly Voice
Matinas BioPharma Holdings, Inc. Notifies NYSE American of Non-Compliance with Continued Listing Standards - Quiver Quantitative
Matinas BioPharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline - Stock Titan
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):